The Impact Of Therapy On T-cell Recognition Of Mutated Tumour Neo-antigens
Funder
National Health and Medical Research Council
Funding Amount
$1,126,685.00
Summary
Cancer is caused by mutations which should be 'seen' and destroyed by the patients immune cells, similar to how immune cells protect us against viruses. But they don't. This grant will study how current cancer treatments help the immune cells 'see' these mutations. We will undertake these studies in the important cancers lung cancer and mesothelioma.
Compartmental Analysis Of T-cell Responses In Thoracic Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$851,403.00
Summary
To improve immune therapy for cancer we have to be able to determine how cancer patients ‘see’ mutated cancer proteins. Blood is the easiest & most useful source of immune ‘killer’ cells for that task, but the lymph node that drains the tumour and the fluid that bathes a tumour probably contain a much higher number of these killer cells than blood. If so, studying them would help us better track responses to therapy and enable us to choose the best mutated proteins for a vaccine.